中草药  2015, Vol. 46 Issue (11): 1593-1596
0
  PDF    
糙叶败酱正丁醇部位化学成分研究
马趣环1,2, 石晓峰1,2 , 范彬1, 沈薇1, 刘东彦1, 王新娣1    
1. 甘肃省医学科学研究院药物研究所, 甘肃 兰州 730050;
2. 甘肃中医学院, 甘肃省中药药理与毒理学重点实验室, 甘肃 兰州 730030
摘要目的 研究糙叶败酱Patrinia scabra根及根茎的化学成分。方法 利用大孔吸附树脂、硅胶及Sephadex LH-20凝胶柱色谱对其化学成分进行分离、纯化, 根据理化性质及波谱数据进行结构鉴定。结果 从糙叶败酱水提取物的正丁醇萃取部位分离得到12个化合物, 分别鉴定为5-O-阿魏酰奎宁酸(1)、7α-莫诺苷(2)、7β-莫诺苷(3)、白花败酱醇(4)、原儿茶酸(5)、β-胡萝卜苷(6)、isopatriscabroside I(7)、patriscabroside I(8)、patrinioside(9)、松脂醇-4,4'-二-O-β-D-葡萄糖苷(10)、落叶松脂醇-4'-O-β-D-葡萄糖苷(11)、villosolside(12)。结论 糙叶败酱正丁醇部位以环烯醚萜类化合物居多, 其中, 化合物26为首次从该植物中分离得到, 化合物1为首次从败酱科败酱属植物中分离得到。
关键词糙叶败酱     5-O-阿魏酰奎宁酸     7α-莫诺苷     白花败酱醇     原儿茶酸     落叶松脂醇-4'-O-β-D-葡萄糖苷    
Chemical constituents of n-butanol fraction from Patrinia scabra
MA Qu-huan1,2, SHI Xiao-feng1,2, FAN Bin1, SHEN Wei1, LIU Dong-yan1, WANG Xin-di1    
1. Institute of Materia Medica, Gansu Academy of Medical Science, Lanzhou 730050, China;
2. Key Laboratory of Chinese Materia Medica Pharmacology and Toxicology of Gansu Province, Gansu College of Traditional Chinese Medicine, Lanzhou 730030, China
Abstract: Objective To study the chemical constituents of ethyl acetate fraction from Patrinia scabra. Methods Chemical constituents were isolated and purified by macroporous resin, silica gel, and Sephadex LH-20 column chromatography. Their structures were elucidated on the basis of spectroscopic analysis and chemical evidence. Results Twelve compounds were isolated and purified. Their structures were identified as 5-O-feruloylquinic acid (1), 7α-morroniside (2), 7β-morroniside (3), villosol (4), protocatechuic acid (5), β-daucosterol (6), isopatriscabroside I (7), patriscabroside I (8), patrinioside (9), pinoresinol-4,4'-di-O-β-D-glucopyranoside (10), lariciresinol-4'-O-β-D-glucopyranoside (11), and villosolside (12). Conclusion Compounds 26 are isolated from this plant for the first time and the compound 1 is isolated from the plants of Patrinia Juss. (Valerianaceae) for the first time.
Key words: Patrinia scabra Bunge     5-O-feruloylquinic acid     7α-morroniside     villosol     protocatechuic acid     lariciresinol-4'-O-β-D- glucopyranoside    

糙叶败酱Patrinia scabra Bunge为败酱科(Valerianaceae)败酱属Patrinia Juss. 植物,分布于河北、山西及甘肃等地,具有清热解毒、消痈排脓、祛瘀止痛等功效,民间用于治伤寒、温症、跌打损伤、妇女崩中、赤白带下等症。因其治疗崩中带下疗效显著,有“起死回生之功效”,故与其同属植物异叶败酱俗称“墓头回”[1]。近年来,国内对糙叶败酱的药理作用进行了广泛的研究,发现糙叶败酱具有抑菌、抗肿瘤、止血、免疫调节及镇静等多方面的药理作用[2]。为更好地开发和利用我国糙叶败酱植物资源,本课题组比较了糙叶败酱提取物糙叶败酱粗多糖、糙叶败酱总木脂素、糙叶败酱总皂苷的体外抗肿瘤活性,结果表明糙叶败酱不同成分有不同的抗肿瘤作用,且作用显著[3]。而将糙叶败酱 中皂苷量为48.4%的大孔吸附树脂提取物作用于荷瘤小鼠,生命延长率增加,红细胞自然免疫活性得到改善,有一定的红细胞免疫调节作用[4]。鉴于糙叶败酱良好的抗肿瘤及免疫调节作用,本实验对其皂苷成分丰富的正丁醇部位进行化学成分研究,从中分离鉴定出12个化合物,分别鉴定为5-O-阿魏酰奎宁酸(5-O-feruloylquinic acid,1)、7α-莫诺苷(7α-morroniside,2)、7β-莫诺苷(3)、白花败酱醇(villosol,4)、原儿茶酸(protocatechuic acid,5)、β-胡萝卜苷(β-daucosterol,6)、isopatriscabroside I(7)、patriscabroside I(8)、patrinioside(9)、松脂醇-4,4′-二-O-β-D-葡萄糖苷(pinoresinol-4,4′-di-O- β-D-glucopyranoside,10)、落叶松脂醇-4′-O-β-D-葡萄糖苷(lariciresinol-4′-O-β-D-glucopyranoside,11)、villosolside(12)。糙叶败酱正丁醇部位以环烯醚萜类化合物居多,化合物26为首次从该植物中分离得到,化合物1为首次从败酱科败酱属植物中分离得到。

1 仪器和材料

Varian Inova-600 MHz核磁共振仪(TMS内标,美国瓦里安公司);Brucker Daltonics Apex II质谱仪(美国Varian公司);ZF-20D暗箱式紫外分析仪(巩义市予华仪器有限责任公司);BSZ-40自动部分收集仪(上海沪西分析仪器厂);D-101净品型大孔吸附树脂(天津市海光化工有限公司);葡聚糖凝胶Sephadex LH-20(Pharmacia公司);薄层色谱用硅胶GF254、柱色谱用硅胶(100~200、200~300目)均为青岛海洋化工厂产品。所用试剂均为分析纯。

药材于2006年7月采自甘肃省兰州市兴隆山区,植物标本由甘肃省医学科学研究院石长栓研究员鉴定为糙叶败酱Patrinia scabra Bunge的根及根茎,标本存放于甘肃省医学科学研究院标本室。

2 提取与分离

糙叶败酱根及根茎晾干,粉碎(10目),取60 kg加8倍量水煎煮3次,每次2 h。合并提取液,减压浓缩至小体积,加入95%乙醇,使其溶液总含醇量达到70%,静置,滤过,滤液减压浓缩成浸膏。然后将浸膏溶于4 L温水中(低于60 ℃)。依次用石油醚、氯仿、醋酸乙酯、正丁醇进行萃取。将正丁醇萃取物(88 g)分散于水中,过D-101大孔吸附树脂柱,依次用水、10%~60%乙醇、70%丙酮洗脱。其中D-101柱的水(11.39 g)、10%乙醇(9.12 g)、20%乙醇(2.69 g)、30%乙醇(4.1 g)洗脱部分分别通过硅胶柱色谱和Sephadex LH-20柱色谱,以二氯甲烷-甲醇系统反复分离纯化,从水洗脱部分中分离得到化合物2(8.2 mg)、3(8.2 mg)、9(11 mg),从10%乙醇洗脱部分中分离得到化合物5(11 mg)、12(22 mg),从20%乙醇洗脱部分中分离得到化合物4(24 mg)、7(14 mg)、8(11.2 mg),从30%乙醇洗脱部分中分离得到化合物1(10.8 mg)、6(11 mg)、10(13 mg)、11(15.8 mg)。

3 结构鉴定

化合物1:白色粉末,甲醇溶解,EI-MS m/z: 368 [M]+ (11.96),350 [M-H2O]+ (4.10),181 [M-C10H9O3]+ (25),180 [M-C10H9O3-H]+ (90),163 [M-C10H9O3-H2O]+ (100),162 [M-C10H9O3-H2O-H]+ (57.89)。1H-NMR (600 MHz,CD3OD) δ: 7.51 (1H,d,J = 16.2 Hz,H-8′),7.03 (1H,d,J = 1.8 Hz,H-2′),6.93 (1H,dd,J = 8.4,1.8 Hz,H-6′),6.76 (1H,d,J = 8.4 Hz,H-5′),6.19 (1H,d,J = 16.2 Hz,H-7′),5.25 (1H,m,H-5),4.11 (1H,m,H-3),3.71 (1H,dd,J = 7.8,3.0 Hz,H-4),3.69 (3H,s,3′-OCH3),2.12 (4H,m,H-2,6);13C-NMR (150 MHz,CD3OD) δ: 175.4 (-COOH),168.3 (C-9′),149.7 (C-3′),147.2 (C-8′),146.9 (C-4′),127.6 (C-1′),123.0 (C-6′),116.5 (C-5′),115.1 (C-2′),115.0 (C-7′),75.8 (C-1),72.5 (C-5),72.1 (C-3),70.3 (C-4),52.9 (3′-OCH3),38.0 (C-2,6)。以上数据与文献报道一致[5, 6],故鉴定化合物1为5-O-阿魏酰奎宁酸。

化合物2:白色无定形粉末,ESI-MS m/z: 429.137 1 [M+Na]+1H-NMR (600 MHz,CD3OD) δ: 5.83 (1H,d,J = 9.0 Hz,H-1),7.51 (2H,d,J = 3.0 Hz,H-3),2.82 (1H,dt,J = 7.8,4.8 Hz,H-5),1.18 (1H,d,J = 3.0 Hz,H-6a),2.03 (1H,d,J = 10.8 Hz,H-6b),4.80 (1H,d,J = 7.8 Hz,H-7),3.96 (1H,d,J = 6.6 Hz,H-8),1.76 (2H,m,H-9),1.39 (3H,d,J = 7.2 Hz,H-10),4.78 (2H,d,J = 8.0 Hz,H-1′),3.20~3.40 (8H,m,H-2′~5′),3.66 (2H,dd,J = 12.0,6.0 Hz,H-6′a),3.88 (2H,d,J = 12.0 Hz,H-6′b);13C-NMR (150 MHz,CD3OD) δ: 97.1 (C-1),154.5 (C-3),110.9 (C-4),32.0 (C-5),37.3 (C-6),95.9 (C-7),75.1 (C-8),39.9 (C-9),19.9 (C-10),168.7 (C-11),100.1 (C-1′),74.2 (C-2′),78.0 (C-3′),71.6 (C-4′),78.5 (C-5′),62.8 (C-6′)。以上数据与文献报道基本一致[7, 8, 9],故鉴定化合物2为7α-莫诺苷。

化合物3:白色无定形粉末,ESI-MS m/z: 429.137 1 [M+Na]+1H-NMR (600 MHz,CD3OD) δ: 5.87 (1H,d,J = 9.0 Hz,H-1),7.51 (2H,d,J = 3.0 Hz,H-3),3.23 (1H,dt,J = 7.8,4.8 Hz,H-5),1.77 (1H,dd,J = 11.4,4.2 Hz,H-6a),2.03 (1H,d,J = 10.8 Hz,H-6b),5.24 (1H,d,J = 3.0 Hz,H-7),4.88 (1H,d,J = 7.2 Hz,H-8),1.76 (2H,m,H-9),1.32 (3H,d,J = 6.6 Hz,H-10),4.78 (2H,d,J = 8.0 Hz,H-1′),3.20~3.40 (8H,m,H-2′,3′,4′,5′),3.66 (2H,dd,J = 12.0,6.0 Hz,H-6′a),3.88 (2H,d,J = 12.0 Hz,H-6′b);13C-NMR (150 MHz,CD3OD) δ: 95.6 (C-1),154.5 (C-3),110.9 (C-4),27.5 (C-5),34.6 (C-6),92.4 (C-7),65.9 (C-8),40.6 (C-9),19.8 (C-10),168.7 (C-11),100.1 (C-1′),74.2 (C-2′),78.0 (C-3′),71.7 (C-4′),78.5 (C-5′),62.9 (C-6′)。以上数据与文献报道基本一致[7, 8, 9],故鉴定化合物3为7β-莫诺苷。

化合物4:白色粉末,氯仿溶解,碘蒸气显色,mp 139~141 ℃。ESI-MS m/z: 200 [M]+1H-NMR (600 MHz,CDCl3) δ: 4.53 (1H,d,J = 12.4 Hz,H-1a),4.30 (1H,dd,J = 12.4,5.6 Hz,H-1b),2.82~2.88 (1H,m,H-4,5),1.49~1.67 (2H,m,H-6),3.76 (1H,t,J = 4.4 Hz,H-7),2.28 (1H,q,J = 6.4 Hz,H-9),1.23 (3H,s,H-10),1.03 (3H,d,J = 6.4 Hz,H-11);13C-NMR (150 MHz,CDCl3) δ: 64.5 (C-1),175.3 (C-3),44.9 (C-4),35.9 (C-5),33.4 (C-6),77.7 (C-7),80.4 (C-8),37.6 (C-9),21.5 (C-10),12.2 (C-11)。以上数据与文献报道基本一致[10],故鉴定化合物4为白花败酱醇。

化合物5:白色针晶,三氯化铁-铁氰化钾反应呈阳性,提示化合物含有酚羟基。1H-NMR (600 MHz,CD3OD) δ: 6.88 (1H,d,J = 8.4 Hz,H-5),7.43 (1H,dd,J = 8.4,1.6 Hz,H-6),7.45 (1H,d,J = 1.6 Hz,H-2);13C-NMR (150 MHz,CD3OD) δ: 115.5 (C-5),117.3 (C-2),122.9 (C-1),123.5 (C-6),145.5 (C-3),150.7 (C-4),168.1 (C-7)。以上数据与文献报道基本一致[11],故鉴定化合物5为原儿茶酸。

化合物6:白色粉末,mp 287~289 ℃。Molish和Libermann-Burchard反应均呈阳性,提示该化合物为甾体皂苷类化合物。与β-胡萝卜苷对照品对照,在多种溶剂体系中展开Rf值均一致,混合熔点不下降,故鉴定化合物6为β-胡萝卜苷。

化合物7:白色粉末,ESI-MS m/z: 385 [M+Na]+1H-NMR (600 MHz,CD3OD) δ: 4.43 (1H,d,J = 12.6 Hz,H-1a),4.31 (1H,dd,J = 10.8,6.0 Hz,H-1b),3.29 (1H,m,H-4),3.19 (1H,m,H-5),1.96 (1H,dt,J = 12.6,6.6 Hz,H-6a),2.13 (1H,m,H-6b),3.85 (1H,m,H-7),2.41 (1H,dd,J = 13.5,6.6 Hz,H-9),1.36 (3H,s,H-10),1.13 (3H,t,J = 6.6 Hz,H-11),4.32 (1H,d,J = 6.0 Hz,H-1′),3.17 (1H,t,J = 7.8 Hz,H-2′),3.26~3.36 (3H,m,H-3′~5′),3.85 (1H,m,H-6′a),3.67 (1H,dd,J = 12.0,5.4 Hz,H-6′b);13C-NMR (150 MHz,CD3OD) δ: 67.4 (C-1),179.3 (C-3),39.9 (C-4),40.5 (C-5),37.4 (C-6),88.7 (C-7),81.6 (C-8),46.2 (C-9),22.7 (C-10),14.1 (C-11),105.0 (C-1′),75.4 (C-2′),78.1 (C-3′),71.7 (C-4′),77.9 (C-5′),62.8 (C-6′)。以上数据与文献报道基本一致[7, 8],故鉴定化合物7为isopatriscabroside I。

化合物8:白色无定形粉末,ESI-MS m/z: 385 [M+Na]+1H-NMR (600 MHz,CD3OD) δ: 4.40 (1H,m,H-1a),4.42 (1H,m,H-1b),2.57 (1H,dq,J = 12.0,6.0 Hz,H-4),2.02 (1H,m,H-5),1.89 (1H,m,H-6a),2.02 (1H,d,J = 4.8 Hz,H-6b),4.19 (1H,t,J = 4.8 Hz,H-7),2.47 (1H,td,J = 10.2,7.2 Hz,H-9),1.36 (3H,s,H-10),1.11 (3H,d,J = 7.8 Hz,H-11),4.47 (1H,d,J = 4.8 Hz,H-1′),3.13 (1H,t,J = 8.4 Hz,H-2′),3.23~3.34 (3H,m,H-3′~5′),3.83 (1H,d,J = 12.6 Hz,H-6′a),3.63 (1H,dd,J = 12.6,6.0 Hz,H-6′b);13C-NMR (150 MHz,CD3OD) δ: 67.6 (C-1),179.3 (C-3),39.8 (C-4),40.0 (C-5),37.3 (C-6),88.4 (C-7),78.4 (C-8),47.2 (C-9),18.2 (C-10),14.2 (C-11),99.0 (C-1′),75.1 (C-2′),78.0 (C-3′),71.7 (C-4′),77.8 (C-5′),62.8 (C-6′)。以上数据与文献报道基本一致[7, 8],故鉴定化合物8为patriscabroside I。

化合物9:白色无定形粉末,ESI-MS m/z: 471.220 9 [M+Na]+1H-NMR (600 MHz,CD3OD) δ: 3.40 (1H,m,H-1a),3.96 (1H,m,H-1b),4.88 (1H,s,H-3a),5.24 (1H,s,H-3b),2.83 (1H,s,H-5),1.77 (1H,m,H-6a),2.04 (1H,m,H-6b),4.45 (1H,m,H-7),2.52 (1H,m,H-9),1.51 (3H,s,H-10),3.96 (1H,m,H-11a),4.12 (1H,m,H-11b),2.16 (2H,m,H-2′a),2.05 (1H,m,H-3′),0.97 (6H,m,H-4′,5′),4.11 (1H,m,H-1″),3.14 (1H,m,H-2″),3.20~3.38 (3H,m,H-3″~5″),3.65 (1H,m,H-6″a),3.86 (1H,m,H-6″b);13C-NMR (150 MHz,CD3OD) δ: 69.7 (C-1),111.8 (C-3),154.5 (C-4),40.2 (C-5),37.3 (C-6),77.9 (C-7),95.6 (C-8),51.7 (C-9),19.2 (C-10),65.9 (C-11),168.7 (C-1′),43.8 (C-2′),25.9 (C-3′),22.7 (C-4′,5′),100.1 (C-1″),75.2 (C-2″),78.0 (C-3″),71.5 (C-4″),77.8 (C-5″),62.8 (C-6″)。以上数据与文献报道基本一致[7],故鉴定化合物9为patrinioside。

化合物10:白色粉末,ESI-MS m/z: 705 [M+Na]+1H-NMR (600 MHz,DMSO-d6) δ: 7.07 (2H,s,H-2,2′),6.84 (2H,d,J = 8.4 Hz,H-5,5′),7.03 (2H,d,J = 8.0 Hz,H-6,6′),4.84 (2H,m,H-7,7′),3.23 (2H,m,H-8,8′),4.13 (2H,m,H-9),3.77 (2H,m,H-9′),3.78 (3H,s,OCH3),4.87 (2H,d,J = 4.8 Hz,H-1″,1′′′);13C-NMR (150 MHz,DMSO-d6) δ: 135.5 (C-1,1′),110.6 (C-2,2′),149.2 (C-3,3′),146.1 (C-4,4′),115.4 (C-5,5′),118.4 (C-6,6′),85.1 (C-7,7′),53.9 (C-8,8′),71.3 (C-9,9′),55.8 (OCH3),100.4 (C-1″,1′′′),73.3 (C-2″,2′′′),77.2 (C-3″,3′′′),69.8 (C-4″,4′′′),76.9 (C-5″,5′′′),60.8 (C-6″,6′′′),55.8,53.9 (2× OCH3)。以上数据与文献报道基本一致[12],故鉴定化合物10为松脂醇-4,4′-二-O-β-D-葡萄糖苷。

化合物11:白色粉末,ESI-MS m/z: 545.200 0 [M+Na]+,561.194 8 [M+K]+1H-NMR (600 MHz,DMSO-d6) δ: 6.80 (1H,d,J = 2.4 Hz,H-2),6.68 (1H,d,J = 8.0 Hz,H-5),6.49 (1H,d,J = 10.2 Hz,H-6),2.48 (1H,dd,J = 13.6,11.6 Hz,H-7a),2.78 (1H,d,J = 9.0 Hz,H-7b),2.68 (1H,m,H-8),3.78 (1H,m,H-9a),3.57 (1H,m,H-9b),7.00 (1H,d,J = 6.4 Hz,H-2′),7.12 (1H,d,J = 8.4 Hz,H-5′),6.88 (1H,dd,J = 8.0,2.0 Hz,H-6′),4.84 (1H,d,J = 9.6 Hz,H-7′),2.48 (1H,m,H-8′),3.64~3.75 (1H,m,H-9′),3.78 (3H,s,3-OCH3),3.74 (3H,s,5′-OCH3),4.85 (2H,d,J = 7.6 Hz,H-1″);13C-NMR (150 MHz,DMSO-d6) δ: 132.6 (C-1),112.3 (C-2),147.3 (C-3),144.7 (C-4),116.5 (C-5),121.4 (C-6),32.2 (C-7),45.3 (C-8),73.2 (C-9),136.5 (C-1′),110.5 (C-2′),148.8 (C-3′),145.6 (C-4′),118.4 (C-5′),119.1 (C-6′),83.1 (C-7′),54.0 (C-8′),60.7 (C-9′),55.6,55.7 (2×OCH3),100.1 (C-1″),73.2 (C-2″),77.0 (C-3″),69.5 (C-4″),76.5 (C-5″),60.7 (C-6″)。以上数据与文献报道基本一致[12],故鉴定化合物11为落叶松脂醇-4′-O-β-D-葡萄糖苷。

化合物12:白色针状结晶(丙酮),ESI-MS m/z: 200 [M]+1H-NMR (600 MHz,CD3COCD3) δ: 4.53 (1H,d,J = 12.4 Hz,H-1a),4.30 (1H,dd,J = 12.4,5.6 Hz,H-1b),2.82~2.88 (1H,m,H-4,5),1.49~1.67 (2H,m,H-6),3.76 (1H,t,J = 4.4 Hz,H-7),2.28 (1H,q,J = 6.4 Hz,H-9),1.23 (3H,s,H-10),1.03 (3H,d,J = 6.4 Hz,H-11);13C-NMR (150 MHz,CD3COCD3) δ: 65.1 (C-1),176.2 (C-3),45.9 (C-4),35.2 (C-5),31.1 (C-6),73.8 (C-7),85.7 (C-8),37.8 (C-9),18.1 (C-10),13.1 (C-11),97.4 (C-1′),74.5 (C-2′),76.8 (C-3′),70.3 (C-4′),76.7 (C-5′),61.3 (C-6′)。以上数据与文献对照基本一致[13],故鉴定化合物12为villosolside。

参考文献
[1] 国家中医药管理局《中华本草》编委会. 中华本草 [M]. 上海: 上海科学技术出版社, 1999.
[2] 马趣环, 石晓峰, 范彬, 等. 糙叶败酱化学成分及药理活性研究进展 [J]. 中国药师, 2010, 13(6): 879-881.
[3] 陈茹, 赵健雄, 王学习. 糙叶败酱提取物的体外抗肿瘤活性比较 [J]. 四川中医, 2011, 29(1): 50-52.
[4] 王学习, 赵健雄, 程卫东, 等. 糙叶败酱大孔吸附树脂提取物对荷瘤小鼠红细胞膜CD35和CD44s的影响 [J]. 中药材, 2007, 30(11): 1414-1417.
[5] Morishita H, Iwahashi H, Osaka N, et al. Chromatographic separation and identification of naturally occurring chlorogenic acids by 1H nuclear magnetic resonance spectroscopy and mass spectrometry [J]. J Chromatogr, 1984, 315(12): 253-260.
[6] Iwai K, Kishimoto N, Kakino Y, et al. In vitro antioxidative effects and tyrosinase inhibitory activities of seven hydroxycinnamoyl derivatives in green coffee beans [J]. J Agric Food Chem, 2004, 52(15): 4893-4898.
[7] 邸磊. 糙叶败酱化学成分及其抗肿瘤活性研究 [D]. 合肥: 安徽大学, 2012.
[8] Kouno I, Yasuda I, Mizoshiri H, et al. Two new iridolactones and their glycosides from the roots of Patrinia scabra [J]. Phytochemistry, 1994, 37(2): 467-472.
[9] 宋丹丹, 杨炳友, 杨柳. 接骨木根皮的化学成分研究 [J]. 中医药信息, 2014, 31(3): 4-6.
[10] 李娜. 白花败酱草化学成分, 抗炎作用以及总皂苷提取纯化工艺研究 [D]. 成都: 成都中医药大学, 2006.
[11] 刘东彦, 石晓峰, 李冲, 等. 雪松松针醋酸乙酯部位化学成分研究 [J]. 中草药, 2011, 42(10): 1921-1924.
[12] 李廷钊, 张卫东, 顾正兵, 等. 糙叶败酱中木脂素成分研究 [J]. 中草药, 2005, 36(3): 338-340.
[13] 徐成俊, 曾宪仪, 于德泉. 白花败酱的化学成分研究 [J]. 药学学报, 1985, 20(9): 652.